Every Form 4 that Ocugen, Inc. (OCGN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow OCGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OCGN filings page.
Ocugen, Inc. (OCGN) reported that Chief Executive Officer and director Shankar Musunuri sold a total of 525,991 shares of common stock on September 9, 2026 in open-market or private transactions pursuant to a Rule 10b5-1 trading plan adopted on June 5, 2026.
The sales included 468,727 shares held directly at a weighted average price of $1.12 per share, with prices ranging from $1.06 to $1.31, and 57,264 shares held indirectly through KVM Holdings, LLC at a weighted average price of $1.12 per share, with prices ranging from $1.11 to $1.14. After these transactions, Musunuri held 4,487,197 shares directly and 1,088,035 shares indirectly through KVM Holdings, LLC, over which he has voting and investment power.
Ocugen, Inc. Chief Financial Officer Treerita Essalima Johnson-Greene bought 21,000 shares of Common Stock in an open-market purchase at $1.23 per share. Following this transaction, she directly holds 521,000 shares and has indirect ownership of 350 shares held by her spouse.
Ocugen, Inc. director Uday Kompella received a grant of stock options covering 170,100 shares of common stock. The options have an exercise price of $1.22 per share and expire on June 11, 2036.
The award vests upon the earlier of June 11, 2027 or Ocugen’s next annual meeting of stockholders, provided he continues serving through the vesting date. Following this grant, Kompella holds 170,100 options directly.
Ocugen, Inc. director Chandrasekhar Satishchandran received a grant of stock options covering 170,100 shares of common stock. The options have an exercise price of $1.22 per share and expire on June 11, 2036.
The award vests upon the earlier of June 11, 2027 or Ocugen’s next annual meeting of stockholders, subject to his continued service through the vesting date. After this grant, his reported derivative holdings in this award total 170,100 options.
Ocugen, Inc. director Kirsten Castillo received a grant of stock options as equity compensation. The award covers 170,100 options to buy common stock at an exercise price of $1.22 per share, expiring on June 11, 2036.
The options vest upon the earlier of June 11, 2027 or Ocugen’s next annual meeting of stockholders, provided she continues to serve through the vesting date. Following this grant, she holds 170,100 derivative securities related to common stock.
Ocugen, Inc. director Junge Zhang received a grant of stock options on June 11, 2026 as part of equity compensation. The award covers 170,100 options to buy common stock at an exercise price of $1.22 per share, expiring on June 11, 2036. The options vest on the earlier of June 11, 2027 or Ocugen’s next annual meeting of stockholders, contingent on continued service through the vesting date. Following this grant, the filing shows Zhang holding 170,100 derivative securities directly, with no open‑market purchases or sales reported.
Ocugen, Inc. director Blaise Coleman received a new stock option grant covering 170,100 shares of common stock. The option has an exercise price of $1.22 per share and expires on June 11, 2036. This is a compensation-related award, not an open-market purchase.
According to the terms, the option vests upon the earlier of June 11, 2027 or Ocugen’s next annual meeting of stockholders, provided Coleman continues to serve through the applicable vesting date. Following this grant, he holds 170,100 stock options directly.
Ocugen, Inc. director Zhang Junge exercised stock options to acquire additional common shares. On April 1, 2026, he exercised options covering 194,134 shares of common stock at exercise prices of $0.51, $0.46, and $1.42 per share. Following these exercises, he directly owns 1,359,316 common shares. The options had previously vested and become exercisable between January 2020 and June 2025.
Ocugen, Inc. reported new equity awards to its Chief Executive Officer and director, Shankar Musunuri. On January 2, 2026, he received 3,123,201 performance stock units, each representing a contingent right to one share of common stock upon achievement of performance goals and continued service. On the same date, he was also granted an option to buy 3,123,201 shares of common stock at an exercise price of $1.38 per share, vesting annually in equal installments over three years starting January 2, 2027, subject to continued service.
Following these transactions, Musunuri beneficially owned 4,955,924 shares of Ocugen common stock directly and 1,145,299 shares indirectly through KVM Holdings, LLC, where he has voting and investment power over the shares held.